| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1366578 | Bioorganic & Medicinal Chemistry Letters | 2007 | 4 Pages |
Abstract
A novel series of 2-hydroxy-N-arylbenzenesulfonamides were identified to be ATP-citrate lyase (ACL) inhibitors with compound 9 displaying potent in vitro activity (IC50 = 0.13 μM). Chronic oral dosing of compound 9 in high-fat fed mice lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain.
Graphical abstractA novel series of 2-hydroxy-N-arylbenzenesulfonamides were identified to be ATP-citrate lyase (ACL) inhibitors with compound 9 displaying potent in vitro activity (IC50 = 0.13 μM). Chronic oral dosing of compound 9 in high-fat fed mice lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
James J. Li, Haixia Wang, Joseph A. Tino, Jeffrey A. Robl, Timothy F. Herpin, R. Michael Lawrence, Scott Biller, Haris Jamil, Randy Ponticiello, Luping Chen, Ching-hsuen Chu, Neil Flynn, Dong Cheng, Rulin Zhao, Bangchi Chen, Dora Schnur,